Scott Reding

Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX.

Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX.

Nomura Securities International, Inc. (NSI) is a registered broker/dealer headquartered in New York City and was founded in 1969. The firm is a division of Nomura Holding America, Inc. and their ultimate parent is Nomura Holdings, Inc. (NYSE: NMR, TYO: 8604, AMS: 8604). NSI provides securities brokerage services, as well as asset management, domestic retail, global markets, global investment banking and global merchant banking services. The firm's fixed-income business consists of bond sales and trading, origination and product supply for securitization deals and real estate-focused asset finance operations (in cooperation with Investment Banking). In the equity markets, NSI offers sales and trading of domestic and foreign stocks on a global basis, primarily for institutional investors.

Molecular Staging, Inc. (MSI) developed products for the detection & measurement of proteins and nucleic acids. The company's amplification technologies included products & services that identify individual and multiplexed sets of biomarkers & a method of generating DNA from a few cells. MSI enabled transformational products and services across multiple health care markets. The company was founded in 1998 and was located in New Haven, CT.

Part of Sarepta Therapeutics, Inc., Immunotherapy Corp. develops cancer treatments. The company is based in Seattle, WA. The CEO of the company is Amnon Gonenne. Immunotherapy was acquired by AntiVirals, Inc. on November 06, 1997 for $24 million.